Who is sponsoring NCT05699122?

NCT05699122 is sponsored by Hospital Israelita Albert Einstein.

What drugs are being tested in NCT05699122?

Interventions in NCT05699122: Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis, Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss, Low Level Laser Therapy - Persistent erythema with intact epidermis, Low Level Laser Therapy - Erythema with signs of epidermis loss.

What condition does NCT05699122 study?

NCT05699122 studies Dermatitis.

Is NCT05699122 still recruiting?

NCT05699122 is currently completed. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT05699122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Low-level Laser Therapy in the Treatment of Incontinence-associated Dermatitis in the Elderly

Completed NA Last updated 13 September 2023

What this trial tests

NA trial testing Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis in Dermatitis in 16 participants. Completed in 30 June 2023.

Timeline

1 February 2023

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	Hospital Israelita Albert Einstein
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	16
Start date	1 February 2023
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across Brazil

Drugs / interventions tested

Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis
Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss
Low Level Laser Therapy - Persistent erythema with intact epidermis
Low Level Laser Therapy - Erythema with signs of epidermis loss

Conditions studied

Dermatitis — all drugs for Dermatitis →

Sponsor

Hospital Israelita Albert Einstein

Who can join

Adults 60 to 100, any sex, with Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Incontinence-associated dermatitis (IAD) is defined as skin inflammation resulting from prolonged exposure to feces and/or urine, found in individuals with urinary incontinence, fecal incontinence, or both. Currently, preventive and treatment measures with strong clinical evidence include gentle hygiene and application of barrier products. Justification: Low-Level Laser Therapy (LLLT) is used in the tissue repair process, due to its analgesic, anti-inflammatory and biomodulator effects, with improvement in the treatment of pressure injuries. In this way, would the use of LLLT bring better results associated with topical treatment for the management of IAD?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dermatitis

Currently open trials in the same condition.

NCT07054528 — Multicentre Real-life Data Collection Study With CareMin650™ in the Prevention and Treatment of Oral Mucositis and Radio · active not recruiting
NCT06353087 — Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) · recruiting
NCT01631617 — Effects of Treatments on Atopic Dermatitis · Phase 2 · recruiting

Other Hospital Israelita Albert Einstein trials

Trials by the same sponsor.

NCT07447674 — ED Post-Discharge Digital Follow-Up: A Communication Comparison · NA · not yet recruiting
NCT07398222 — Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study · recruiting
NCT07233837 — Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units · NA · recruiting
NCT06726707 — COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis · Phase 2, PHASE3 · withdrawn
NCT07112846 — Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05699122 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Israelita Albert Einstein
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05699122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing